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ABSTRACT 
Introduction.  Sexual dysfunction in women with diabetes, despite its important consequences to 
their quality of life, has been investigated only recently with conflicting results about its prevalence 
and association with complications and psychological factors. 
 
Aims.  To assess the prevalence of the alteration of sexual function and the influence of metabolic 
control and psychological factors on female sexuality. 
 
Methods.  Seventy-seven adult Italian women with type 1 diabetes, matched with a control group 
(n = 77), completed questionnaires evaluating sexual function (Female Sexual Function Index, 
FSFI), depressive symptoms (Self-Rating Depression Scale, SRDS), social and family support 
(Multidimensional Scale of Perceived Social Support), and diabetes-related quality of life (Diabetes 
Quality of Life). Clinical and metabolic data were collected. 
 
Main Outcome Measures.  Prevalence and magnitude of sexual dysfunction in terms of alteration 
of sexual functioning as measured by the FSFI scores. 
 
Results.  The prevalence of sexual dysfunction was similar in diabetes and control groups (33.8% 
vs. 39.0%, not significant), except for higher SRDS scores in the diabetes group (47.39 ± 11.96 vs. 
43.82 ± 10.66; P = 0.047). Diabetic patients with an alteration of sexual function showed a 
significantly higher SRDS score (53.58 ± 14.11 vs. 44.24± 9.38, P = 0.004). Depression symptoms 
and good glycemic control (A1C < 7.0%) were predictors of alteration of sexual function only in 
diabetic patients (odds ratio [OR] = 1.082; 95% confidence interval [CI]: 1.028–1.140; OR = 5.085; 
95% CI: 1.087–23.789), since we have not found any significant predictor of sexual dysfunction in 
the control group. 
 
Conclusions.  The prevalence of sexual dysfunction in our type 1 diabetes patients' sample is 
similar to those reported in other studies. Diabetic patients are similar to healthy people except for 
higher depression scores. Further studies are necessary to understand whether the correlation 
between an alteration of sexual function and good glycemic control may be related to the role of 
control as a mental attitude. Tagliabue M, Gottero C, Zuffranieri M, Negro M, Carletto S, Picci RL, 
Tomelini M, Bertaina S, Pucci E, Trento M, and Ostacoli L. Sexual function in women with type 1 
diabetes matched with a control group: Depressive and psychosocial aspects. J Sex Med 
2011;8:1694–1700. 
 
 
 
Introduction 
In 1974, the World Health Organization [1] recognized that human sexuality is an important 
element of an individual's health. In recent years, many studies have been conducted about 
prevalence of sexual dysfunction and comorbid mental disorders in patients with diabetes. 
 Researches have initially focused on sexual dysfunction secondary to diabetes in male patients. 
Several studies have indeed shown that men with diabetes are subjected to a higher risk of 
developing erectile dysfunction, especially when other complications of diabetes are present [2]. 
 
Only recently, the sexual function of women with diabetes has been investigated, with results more 
conflicting than for men. 
 
The prevalence of female sexual dysfunction (FSD) in the general population is estimated at 
between 25% and 63% [3]. In the diabetic population, the prevalence varies widely between 
different studies: Nowosielski [4] reports a range between 14% and 85%, in particular in type 1 
diabetes, which varies between 17% and 71%. The prevalence data reported here, as well as those 
resulting from this work, relate more to a change in sexual functioning rather than to a diagnosis of 
FSD. The latter, as evidenced by Giraldi and colleagues [5], would require the assessment of 
distress. 
 
In the same review [5], type 2 diabetes mellitus is demonstrated to have a greater impact on 
women's sexuality than type 1. This, probably, is due to social and psychological factors, problems 
related to age, menopausal status, and comorbidities. 
 
It is unclear whether FSD is correlated to diabetic complications. Enzlin and coworkers wrote that 
women with diabetic complications did not report more sexual dysfunction than did women without 
complications [6]. In subsequent research on both men and women, they found an association 
between the number of complications and the occurrence of sexual dysfunction [7]. 
 
Several studies [4,8] found no association between metabolic control and sexual dysfunction in 
women with diabetes, unlike that reported for men. It appears that the etiology of sexual 
dysfunction in women is mainly related to psychological factors [7–9]. Influences on female 
sexuality are multifactorial and are attributable to biological, psychosocial, and context-related 
factors [10]. Nowosielski [4], in particular, has highlighted the importance of partner-related 
factors. In keeping with this, some researches have noted that sexual dysfunction is linked to having 
a poor relationship with the partner [11], to the duration of the relationship [12], to marital status 
[13], and to the quality of marital relations [6]. 
 
With regard to comorbidity of mental disorders in women with diabetes, several studies [4,6–8,14] 
highlight the correlation between sexual dysfunction and the presence of depressive symptoms [5]. 
Depression is more prevalent in diabetics in comparison with the normal population [15] and 
particularly in women with diabetes compared to men with diabetes [16]. 
 
Finally, there are conflicting results about the prevalence of sexual dysfunction. Some studies show 
a higher prevalence in women with type 1 diabetes as compared to healthy women [6,17], while 
other studies do not show this difference [18,19]. Salonia and colleagues [20] find a difference in 
the prevalence of sexual dysfunction between women with type 1 diabetes and the control group 
only in the luteal phase of the menstrual cycle, whereas in the follicular phase, the prevalence is 
similar. 
 
This work has sought to contribute knowledge on the subject by attempting to neutralize the effect 
of some factors on the presence of sexual dysfunction, on whose role there seems to be moderate 
agreement. Specifically, with regard to the influence of depression, we have chosen not to include 
in the study those subjects diagnosed with depressive disorder. We did this in order to assess the 
actual presence of greater symptomatology in the group of diabetic patients and to understand 
whether the role of these symptoms in female sexual function differs from a healthy population. In 
order to reduce a source of heterogeneity, we have chosen to include only women involved in a 
stable couple relationship for at least 1 year. To take into account certain indicators related to the 
intimate relationship, but not necessarily similar in couples united by stable relations, we also 
investigated perceived social support so that we could evaluate the effective comparability of the 
two samples. 
 
 
Aims 
The aims of this study are to assess (i) the prevalence of sexual dysfunction in terms of alteration of 
sexual functioning in a sample of Italian type 1 diabetic women in comparison with a matched 
control group, the members of both groups being in a stable couple relationship continuing for at 
least 1 year; and (ii) the role of depression symptoms, Diabetic Quality of Life and 
Multidimensional Perceived Social Support on sexual function in the patients' group compared with 
a matched control group. 
 
Were supposed to find no significant difference in the prevalence of sexual dysfunction between the 
type 1 diabetes and the control group in a sample with a stable intimate relationship. 
 
We also hypothesized a significant role of depressive traits relating to sexual dysfunction in diabetic 
patients even in the absence of a depressive disorder. 
 
 
Methods 
We conducted a case-control study with a total of 91 consecutive women with type 1 diabetes 
mellitus who attended seven diabetic centers in Piedmont (Italy) during a 2-month period. The 
study was approved by a local branch of the Italian Diabetes Society (S.I.D.). Eighty-three patients 
were eligible in terms of the following criteria: (i) 18–65 years of age; (ii) a stable couple 
relationship continuing for at least 1 year; and (iii) type 1 diabetes mellitus. We excluded patients 
with major health problems other than complications of diabetes, such as neoplasm, major 
depression or other psychiatric disorders, severe neurological diseases, and drug or alcohol abuse. 
Subsequently, an age- and education-matched group of healthy control women without diabetes (n 
= 77), recruited from women attending the general outpatient departments of the seven centers in 
Piedmont for routine screening reasons and from patients' relatives, was also invited to participate 
in the study. 
 
We distributed the questionnaires to women of childbearing age during the early follicular phase, in 
order to neutralize the influence of hormonal changes on emotional state, as did other authors [21]. 
 
Written informed consent was obtained from all participants prior to administering the 
questionnaires. In order to maintain privacy, a modified version of a self-generating code was used 
[22]. 
 
Instruments 
Patients and control participants were asked to complete four validated multiple-choice 
questionnaires at home and return them within 4 weeks. Established self-report questionnaires were 
used to assess depression, perceived social support, and relevant aspects of sexual function and 
diabetes-related quality of life. The last aspect was inquired only for the diabetic patients. All of the 
questionnaires used were validated for the Italian language. The scores for each instrument were 
calculated by the recommended scoring system. Each questionnaire was explained to the 
participants to ensure that they understood the questions. 
 The Female Sexual Function Index (FSFI) [23,24] is a multidimensional self-reporting instrument 
for assessing the key dimensions of sexual function in women. It includes 19 items subdivided into 
six domains (frequency and degree of sexual desire, subjective arousal, lubrication, orgasm, 
satisfaction, and pain) referring to sexual activity in the last 4 weeks. Responses were graded on a 
scale of 1 (almost never or never) to 5 (almost always or always), where a score of 0 indicated no 
sexual activity. An alteration of sexual function was evidenced by a score 26.55 or less [25]. 
 
The Zung Self-Rating Depression Scale (SRDS) [26,27] is a 20-item self-reporting questionnaire 
that is widely used as a screening tool covering affective, psychological, and somatic symptoms 
associated with depression. It has been effectively used in a variety of settings that include primary 
care, psychiatric treatment, drug trials, and various research situations. For each item, the patient 
specifies the frequency with which the symptom is experienced on a Likert scale ranging from 1 
(rarely) to 4 (most of the time). A total score, ranging from 25 to 100, is derived by adding up the 
score of the individual items and then normalizing them, as suggested by the author. Most people 
with depression score between 62 and 74, while a score of 87 or above indicates severe depression. 
The scores provide indicative ranges of depression severity that can be useful for clinical and 
research purposes. 
 
The Multidimensional Scale of Perceived Social Support (MSPSS) [28,29], evaluates the perception 
of social support, particularly of family, friends, and other significant people. It has 12 items, which 
are divided into three subscales: family, friends, and significant other support. Responses are graded 
on a scale of 0 (completely false) to 5 (completely true). Total scores range from 0 to 84, with 
higher scores indicating a more positive social support. 
 
The Diabetes Quality of Life (DQOL) [30,31] is used to assess a patient's personal experience of the 
impact of diabetes care and treatment on major life domains. The scale consists of 46 items that 
address four major dimensions (satisfaction with treatment, impact of treatment, worries about long-
term complications, and worries about social issues). Each item is rated on a five-point Likert scale 
ranging from 1 (very satisfied) to 5 (very dissatisfied). Higher scores indicate a higher burden of 
diabetes treatment on the patient's quality of life. 
 
A venous blood sample to determine hemoglobin A1c (HbA1C) had been collected from all 
diabetic patients within the last 3 months prior to the day they were invited to participate in this 
study. HbA1C was determined using high-performance liquid chromatography the normal range of 
which is 4.5–6.2 mg/dL. The patients' medical records were used to obtain data on age, education, 
duration of marriage or relationship, previous or current pregnancies or menopausal state, smoking 
habit, years of diabetes, type of insulin and other medications used, presence of complications 
(neuropathy and/or nephropathy and/or retinopathy), and body mass index (BMI). 
 
Power Calculation 
For assessing the power of the test we used G*Power 3 software [32]. To have 90% power to detect 
an effect size of 0.40 in the global FSFI score comparing the women with diabetes with a matched 
healthy control group with two-sided significance level alpha of 0.05, we required 68 participants 
per each paired group. Taking into account the inclusion and exclusion criteria and a possible 
refusal rate, we decided to evaluate approximately 90 patients. 
 
Statistical Analysis 
Analyses were performed using the Statistical Package for Social Sciences (SPSS version 14.0; 
Chicago, IL, USA). Student's t-test and χ2 test were used to calculate differences between case and 
control groups and between patients without sexual dysfunction (FSFI > 26.55) and patients with an 
alteration of sexual function (FSFI ≤ 26.55). To study the predictors of sexual functioning in both 
groups, two binary logistic regressions were employed, taking the presence of sexual dysfunction as 
a dependent variable, and taking as independent variables are age, depression, the menopausal 
condition, and for the diabetic group only, complications and good glycemic control (A1C < 7.0%). 
 
 
Results 
Of 83 type 1 diabetes patients, 77 (response rate: 93%) agreed to participate and took the 
questionnaires home. Six refused to participate. All the 77 healthy control women without diabetes 
agreed to participate in the study. 
 
The patients' baseline characteristics and the differences between the two groups are depicted in 
Table 1. 
 
The patients' baseline characteristics and the differences between the two groups are depicted in Table 1. 
  
Case group Control group 
t-test/χ2P 
n = 77 n = 77 
 †Data are means ± SD or n (%). 
 ‡Possible scores range from 19 to 95, with higher scores indicating better sexual function. 
 §Considered as FSFI score ≤ 26.55. 
 ¶Possible scores range from 25 to 100, with higher scores indicating more severe symptoms. 
 ††Possible scores range from 1 to 28, with higher scores indicating higher perceived social support. 
 FSFI = Female Sexual Function Index; SDRS = Self-Rating Depression Scale; MSPSS = Multidimensional Scale of Perceived 
Social Support; HbA1C = hemoglobin A1c; n.s = not significant. 
Age in years 39.35 ± 9.77 40.22 ± 9.54 n.s. 
Education     n.s 
 Primary school 1 (1.3) 1 (1.3)   
 Secondary school 17 (22.1) 17 (22.1)   
 High school 43 (55.8) 43 (55.8)   
 University degree 16 (20.8) 16 (20.8)   
Duration of sexual relationship 12.06 ± 9.04 15.56 ± 9.90 0.029 
At least one pregnancy 34 (44.2) 47 (61.0) 0.004 
Number of pregnancies 1.21 ± 1.20 2.06 ± 1.21 0.012 
Women in menopausal state 9 (11.7) 10 (13.0) n.s. 
Actual smokers 23 (29.9) 21 (27.3) n.s. 
FSFI score‡ 25.99 ± 7.76 26.58 ± 8.97 n.s. 
  
There was no significant difference in the prevalence of sexual dysfunction, in terms of the 
reporting of more symptoms of FSD. In the diabetes group, we found 26 patients (33.8%) with a 
FSFI score ≤ 26.55 and 51 patients (66.2%) with a higher FSFI score. In the control group, there 
were 30 women (39.0%) with a FSFI score ≤ 26.55 and 47 women (61.0%) with a higher score. In 
addition, the mean FSFI score is similar in the two groups (25.99 ± 7.76 vs. 26.58 ± 8.97). Diabetic 
women reported more depressive symptoms (SRDS score: 47.39 ± 11.96 vs. 43.82 ± 10.66; P = 
0.047), while the scores of perceived social support (MSPSS score: 16.16 ± 4.35 vs. 15.80 ± 4.53) 
were similar in the two groups. 
 
We divided diabetic women into two subgroups based on the presence of FSD (FSFI score ≤ 26.55). 
Both subgroups were similar in respect to the main characteristics: age, BMI, number of women in 
menopausal state, duration of disease, A1C, complications, previous pregnancies, MSPSS total 
score, and DQOL score (Table 2). In particular, we found that five (9.8%) diabetic patients without 
sexual dysfunction, and six (23.1%) diabetic patients with sexual dysfunction had presented good 
glycemic control (A1C < 7.0%). 
 
 
  
Diabetic patients without sexual 
dysfunction‡(n = 51) 
Diabetic patients with sexual 
dysfunction§(n = 26) 
P 
 †Data are means ± SD or n (%). 
 ‡FSFI score > 26.55. 
 §FSFI score ≤ 26.55. 
 ¶HbA1C < 7.0%. 
 BMI = body mass index; HbA1C = hemoglobin A1c; MSPSS = Multidimensional Scale of 
Perceived Social Support; DQOL = Diabetes Quality of Life; n.s. = not significant. 
Age (years) 37.90 ± 8.63 42.19 ± 11.33 n.s. 
BMI (kg/m2) 23.94 ± 3.31 23.68 ± 2.89 n.s. 
Sexual dysfunction prevalence§ 26 (33.8) 30 (39.0) n.s. 
SDRS¶ 47.39 ± 11.96 43.82 ± 10.66 0.047 
MSPSS total score†† 16.16 ± 4.35 15.80 ± 4.53 n.s. 
Duration of disease in years 17.61 ± 10.11 — — 
HbA1C (%) 8.23 ± 1.10 — — 
HbA1C (%) < 7 11 (14.3) — — 
Diabetes complications 32 (41.6) — — 
Table 1.  Characteristics of the study groups† 
  
Diabetic patients without sexual 
dysfunction‡(n = 51) 
Diabetic patients with sexual 
dysfunction§(n = 26) 
P 
Women in 
menopausal state (%) 
4 (7.8) 5 (19) n.s. 
Duration of disease 
(years) 
17.06 ± 9.63 18.78 ± 11.18 n.s. 
HbA1C (%) 8.12 ± 1.09 7.94 ± 1.24 n.s. 
Good control (%)¶ 5 (9.8) 6 (23.1) n.s. 
Complications (%) 20 (39.2) 13 (50) n.s. 
Previous pregnancy 0.88 ± 0.91 1.17 ± 1.46 n.s. 
MSPSS (total score) 16.81 ± 4.19 14.71 ± 4.41 n.s. 
DQOL (total score) 89.86 ± 20.97 95.00 ± 30.48 n.s. 
Self-Rating 
Depression Scale 
score 
44.24 ± 9.38 53.58 ± 14.11 0.004 
Table 2.  Diabetic women and sexual dysfunction assessed by FSFI† 
 
 
To determine which factors predict the presence of sexual dysfunction in the diabetes group, binary 
logistic regressions were used. Depressive symptoms (odds ratio [OR] = 1.082; 95% confidence 
interval [CI]: 1.028–1.140) and good glycemic compensation (A1C < 7.0%; OR = 5.085; 95% CI: 
1.087–23.789) were associated with a higher likelihood of having sexual dysfunction. Age, number 
of complications, and menopausal state did not reach statistical significance. Neither depressive 
symptoms (OR = 1.033; 95% CI: 0.982–1.088) nor other variables were significant predictors of 
sexual dysfunction in the control group. 
 
 
Discussion 
The prevalence of sexual dysfunction in terms of alteration of sexual functioning in our sample of 
women with type 1 diabetes was similar to those reported by other studies [8,20]. As others have 
reported [18,19,33], we found no significant differences in prevalence between the diabetic and 
control groups. 
 
Few large-scale studies have examined the prevalence of FSD in apparently healthy women in 
Europe [34], in Italy [35] specifically, or in the United States [13]. Apart from age, other factors 
were generally not closely correlated to the presence of FSD, although life changes and distressing 
disorders play an important role. As other reports have indicated [7,36], we found that depression 
was higher in diabetic women than in the control group and affected their sexuality [37]. The Zung 
Self-Rating Depression Scale scores for both control and diabetes groups were not diagnostic of 
major depression (maximum score: 76), which was consistent with the inclusion criteria. As 
Wallner and colleagues [14] have found, women with type 1 diabetes are similar to women in the 
control group except for higher depression scores. In addition, we found that depression is effective 
as a predictor of FSD in the diabetic patients group but not in the control group. 
 
The negative correlation between good glycemic control and sexual dysfunction has no equivalent 
in other studies, which report either no correlation [8] or a close positive correlation [38] between 
sexual dysfunction and poor glycemic control. As we found a trivial lower limit and a very large 
upper limit of the confidence interval, it is difficult to determine the exact size of the differences in 
the two conditions. It is also for this reason that these results may need further specific investigation 
in order to assess whether a firm sense of control efficient for containing HbAlC levels within the 
optimal range can become too generalized—as an attitude—and affect the possibility to experience 
sexual pleasure. 
 
Following Franciosi and colleagues [39], we evaluated the number of complications as determinants 
of the quality of life. Like other studies [6], we found that complications had no influence on sexual 
function, thereby supporting the hypothesis that women's sexual function is predominantly linked to 
sexual context and psychological factors rather than to biological factors [7]. 
 
 
Conclusion 
According to previous studies, the prevalence of sexual dysfunction in terms of alteration of sexual 
functioning was similar in both type 1 diabetes and control groups. However, while it is known that 
depressive aspects play an important role in the sexual lives of people, in our study, depressive 
symptoms are associated with FSD only in the diabetes group. 
 
It is interesting to note the role that the diabetologist is called upon to play in an area that is not yet 
free of taboos, i.e., women's sexuality. This situation is more difficult than the equivalent one in 
male diabetic patients, who report an objective, organic disorder that can be dealt with medically. In 
women, the psychological and depressive component is a better predictor of dysfunction. Therefore, 
a complex evaluation must be made, for which our experience may not have prepared us and in 
which a multidisciplinary approach is surely useful. Thus, the problem of sexuality in the diabetic 
woman runs the risk of being limited to reproductive aspects, in terms of pregnancy as an organic 
event that can be tackled medically. 
 
Finally, there are some limitations to our study. We investigated the distribution of the alteration of 
sexual functioning rather than the prevalence of FSD defined according to diagnostic criteria, since 
to do so would require the assessment of distress. The subjective concerns of diabetic patients were 
investigated as secondary outcomes through the assessment of quality of life. 
 
Furthermore, no account was taken of the time sequence of the onset of sexual dysfunction with 
regard to other variables studied, because it is not possible in a case-controlled study. 
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